Wolf Greenfield

Wolf Greenfield is a law firm specializing exclusively in intellectual property law. Its team includes over 160 professionals with backgrounds in science, technology, and engineering, enabling them to address complex IP issues across various technical fields. The firm provides services in patent prosecution, litigation, trademark and copyright matters, licensing, and post-grant proceedings. Wolf Greenfield serves a diverse client base including multinational corporations, universities, biotech companies, and startups. The firm publishes insights and news related to patent law developments, litigation strategies, and intellectual property policy, reflecting its focus on protecting and advancing clients' IP assets.

Latest from Wolf Greenfield - Page 3

Boardside Chat Thursday

The PTAB will conduct its next Boardside Chat webinar this Thursday, March 21st, from noon to 1 p.m. ET, to discuss hearings before the Board. The presentation will include a virtual tour of the hearing rooms, along

ANPRM an Unnecessary Slog to a Small Rule Package

It has been almost a year since the Patent Trial & Appeal Board (PTAB) released its Advanced Notice of Proposed Rulemaking (ANPRM) on AIA trial practices. As a reminder, the ANPRM

Common AIA Issues Discussed

This coming Thursday January 18th (noon to 1 p.m. (EST)) the PTAB will host its first Boardside Chat of the year. The program will discuss issues that typically arise during an America Invents Act (AIA) proceeding

Avoiding Cellect

The Federal Circuit’s In re Cellect ruling has significant implications for patent portfolios, emphasizing the need for careful planning to avoid obviousness-type double patenting (OTDP) that could compromise statutory term and patent validity. Particularly, patents with patent term

Latent OTDP Issues & Litigation

The Federal Circuit’s decision in In re Cellect clarified that patenting obvious variants of the same invention across multiple patents—Obvious-Type Double Patenting (OTDP)—can result in the elimination/reduction of Patent Term Adjustment (PTA). OTDP was fatal